Real-world outcomes in molecular subgroups for patients with advanced or recurrent endometrial cancer treated with platinum-based chemotherapy
Oncological outcomes differ by molecular groups, in particular among patients with advanced disease. Patients with p53 abnormal tumors have the worst outcome, while patients with POLE mutated tumors have favorable outcomes even with recurrent disease. Implementation of the addition of immunotherapy to chemotherapy is expected to lead to substantial improvement of outcome, particularly in patients with mismatch repair deficient advanced/recurrent disease. There is still a high unmet need in advanced/recurrent patients with p53 abnormal and no specific molecular profile tumors.
Authors
- B. Mascialino (ORCID: https://orcid.org/0000-0003-4154-4728)
- Manohar Pradhan (ORCID: https://orcid.org/0000-0003-1984-9760)
- Gunnar B. Kristensen (ORCID: https://orcid.org/0000-0001-6231-7247)
- Thérese Sørlie (ORCID: https://orcid.org/0000-0002-5995-2319)
- Kari Anne R. Tobin
- Hanne A. Askautrud (ORCID: https://orcid.org/0000-0002-4404-3622)
- Hege Edvardsen
- Kristina Lindemann (ORCID: https://orcid.org/0000-0002-2162-0175)
- Wanja Kildal
- Andreas Kleppe (ORCID: https://orcid.org/0000-0002-8370-5289)
- D. Schneider
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Norwegian Cancer Society (NO)
- GlaxoSmithKline (Italy) (IT)
- GlaxoSmithKline (Switzerland) (CH)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1016/j.ijgc.2024.101618
- Citations
- 6
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.50
Funders
- GlaxoSmithKline